Eisai Co. Ltd.
www.eisai.com
Latest From Eisai Co. Ltd.
Biopharma COVID-19 Collaborations May Avoid Antitrust Hurdles, FTC And DOJ Suggest
FTC and DoJ issue guidance for businesses working together to tackle coronavirus pandemic; BIO is 'pleased' they intend to help facilitate critical partnerships.
Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration
In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments.
Finance Watch: Kymera Will Start Protein Degrader Clinical Trials With $102m VC Round
Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.
Deal Watch: Vir Partnering With Alnylam, WuXi On Coronavirus Treatments
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Therapeutic Areas
- Cancer
- Cardiovascular
- Gastrointestinal
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Inflammation
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Company Type
- Top Japanese Pharma
- Parent & Subsidiaries
- Eisai Co. Ltd.
- Senior Management
-
Haruo Naito, Pres. & CEO
Ryohei Yanagi, CFO
Edward Stewart Geary, CMO - Contact Info
-
Eisai Co. Ltd.
Phone: (81) 3 3817 3700
4-6-10 Koishikawa
Bunkyo-ku
Tokyo, 112-8088
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice